Fate Therapeutics, Inc.
Fate Therapeutics develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Product candidates include FT576 for multiple myeloma and FT522 for lymphoma and autoimmune disorders. CAR T-cell programs target hematologic malignancies, solid tumors, and autoimmune disorders. The company has a collaboration with Ono Pharmaceutical for off-the-shelf CAR T-cell product candidates. Fate Therapeutics was incorporated in 2007 and is headquartered in San Diego, California.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 11.7% in each of the last 6 years.
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
- Unstable profitability: operating margin ranged from -2,222% to -300% over the last 6 years, with operating losses in 6 of them.
- Shareholder dilution: the share count has grown by 5.8% a year over the last three years.
Key Financial Data